開示情報 > Otsuka's JYNARQUE Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing ADPKD

Otsuka's JYNARQUE Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing ADPKD

Otsuka's JYNARQUE Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing ADPKD

開示者 【45780】大塚ホールディングス株式会社
文書名 Otsuka's JYNARQUE Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing ADPKD  
PDF/XBRL [別ウインドウでPDFを開く]
開示日時 2018/04/25 チャネル/カテゴリ 東京証券取引所 /その他
ノート ログインするとIR文書にメモを入力して管理することができます
右上のログインメニューからログインしてください。


開示情報 > Otsuka's JYNARQUE Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing ADPKD